NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
-17.61%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$95.2M
AUM Growth
+$95.2M
(+35%)
Cap. Flow
+$30.8M
Cap. Flow
% of AUM
32.36%
Top 10 Holdings %
Top 10 Hldgs %
78.05%
Holding
60
New
13
Increased
12
Reduced
2
Closed
28
Top Buys
| 1 |
SHPG
Shire pic
SHPG
|
$13.1M |
| 2 |
Viatris
VTRS
|
$6.3M |
| 3 |
CELG
Celgene Corp
CELG
|
$5.5M |
| 4 |
AGN
Allergan plc
AGN
|
$4.91M |
| 5 |
Sanofi
SNY
|
$4.7M |
Top Sells
| 1 |
Merck
MRK
|
$5.49M |
| 2 |
AbbVie
ABBV
|
$3.64M |
| 3 |
Bristol-Myers Squibb
BMY
|
$2.87M |
| 4 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$1.98M |
| 5 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$807K |
Sector Composition
| 1 | Healthcare | 90.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $13.5M | 14% | 135,000 +55,000 | +69% | +$5.5M |
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $13.1M | 13.57% | +76,200 | New | +$13.1M |
|
3
Pfizer
PFE
$141B
| $12.9M | 13.39% | 436,000 +106,000 | +32% | +$3.14M |
|
|
AGN
4
DELISTED
Allergan plc
AGN
| $7.37M | 7.64% | 27,500 +18,300 | +199% | +$4.91M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $6.45M | 6.68% | 101,000 -45,000 | -31% | -$2.87M |
|
|
6
Viatris
VTRS
$12.3B
| $6.3M | 6.53% | +136,000 | New | +$6.3M |
|
|
7
Sanofi
SNY
$121B
| $4.7M | 4.87% | +117,000 | New | +$4.7M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $3.65M | 3.78% | 220,000 +76,000 | +53% | +$1.26M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.61M | 3.74% | 103,000 +13,000 | +14% | +$456K |
|
|
LCI
10
DELISTED
Lannett Company, Inc.
LCI
| $2.69M | 2.79% | +150,000 | New | +$2.69M |
|
|
CNCE
11
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $2.5M | 2.59% | 183,000 | – | – |
|
|
IMGN
12
DELISTED
Immunogen Inc
IMGN
| $1.94M | 2.01% | +228,000 | New | +$1.94M |
|
|
ADMS
13
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $1.69M | 1.75% | +117,000 | New | +$1.69M |
|
14
Neurocrine Biosciences
NBIX
$13.8B
| $1.66M | 1.72% | 42,000 +15,000 | +56% | +$593K |
|
15
uniQure
QURE
$896M
| $1.37M | 1.42% | 115,000 +79,000 | +219% | +$938K |
|
|
IMDZ
16
DELISTED
Immune Design Corp.
IMDZ
| $1.11M | 1.15% | 85,138 +45,138 | +113% | +$587K |
|
|
RXDX
17
DELISTED
Ignyta, Inc.
RXDX
| $1.02M | 1.05% | +150,000 | New | +$1.02M |
|
|
NDRM
18
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $988K | 1.02% | 70,000 +22,000 | +46% | +$311K |
|
|
ADXS
19
DELISTED
Advaxis, Inc.
ADXS
| $903K | 0.94% | 100,000 +44,736 | +81% | +$404K |
|
|
FPRX
20
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $813K | 0.84% | 20,000 -1,500 | -7% | -$61K |
|
21
Iovance Biotherapeutics
IOVA
$807M
| $774K | 0.8% | 152,266 | – | – |
|
|
INFI
22
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $764K | 0.79% | +145,000 | New | +$764K |
|
|
AERI
23
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $733K | 0.76% | 60,280 +32,040 | +113% | +$390K |
|
24
Insmed
INSM
$28.8B
| $507K | 0.53% | +40,000 | New | +$507K |
|
|
PGNX
25
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $419K | 0.43% | +96,000 | New | +$419K |
|